Selected Pharmacogenetic panel test for toxicity prevention of drug-drug interactions between Highly Active Antiretroviral Therapy (HAART) and antiblastic chemotherapy WCRJ 2015; 2 (1): e492
Pharmacogenomics of Cytochrome P450 Family enzymes: implications for drug-drug interaction in anticancer therapy WCRJ 2015; 2 (1): e483
Pharmacogenetic based drug-drug interactions between Highly Active Antiretroviral Therapy (HAART) and antiblastic chemotherapy WCRJ 2014; 1 (4): e386
Comparing methods for isolation of circulating-DNA (C-DNA). Implication of C-DNA as biomarker in the cancer WCRJ 2014; 1 (4): e384
Impact of DPYD variants in Fluoropyrimidine based-therapy: the state of the art WCRJ 2014; 1 (3): e279
Pharmacogenomics markers for prediction response and toxicity in cancer therapy WCRJ 2014; 1 (3): e276
Minimization of the neuropathic effects of oxalipaltin administration agree to cost-effectiveness WCRJ 2014; 1 (3): e264